There is a new phenomenon sweeping the globe (or at least sweeping the imagination of people around the globe). It is the human gut microbiome and the role it may play in the future of human health.
The frequency of nosocomial (acquired in healthcare facility) pneumonia has experienced a steady increase in recent years, and treatment of these infections has become more challenging and expensive due to the emergence of multi-drug resistant bacterial strains.
To help combat decades of stagnation in antibiotic development, a team led by the National Physical Laboratory conducted two studies into the antimicrobial peptides that fight infection in our bodies and the feasibility of using them as the basis for new antibiotic treatment which is less prone to bacterial resistance.
Healthcare-associated infections (HCAI), previously known as hospital acquired infections (HAI), are defined as infections resulting from medical care or treatment in hospital. HCAI may be caused by any infectious agent from endogenous or exogenous sources and affect any part of the body. Five infections: central line-associated blood stream infection, catheter-associated urinary tract infection, surgical site infection, Clostridium difficile infection and healthcare associated pneumonia account for 85% of HCAI1.